No Data
No Data
There Are Reasons To Feel Uneasy About Sanbo Hospital Management Group's (SZSE:301293) Returns On Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondl
Sanbo Neurology (301293.SZ): The project under construction of the new Dongba campus in Beijing is expected to be completed by the end of 2025 and opened in the first quarter of 2026
Gelonghui, May 9 | Sanbo Neurology (301293.SZ) recently said during a survey receiving institutional investors that the company is building a new Beijing Dongba Campus project and is expected to complete construction by the end of 2025 and open in the first quarter of 2026. After the construction of the new hospital area is completed, the scope of medical facilities and medical service business will be expanded. The number of open beds is expected to increase from 254 to 480, and high-end beds will be set up; the number of operating rooms will increase from 6 to 14. At the same time, according to actual business development needs, Beijing Sanbo will add radiotherapy and rehabilitation services in the future. With geographical location, regional space, hardware facilities, medical
Sanbo Neurology (301293.SZ): The company is constructing a new Beijing Dongba campus project and is expected to complete construction by the end of 2025 and open in the first quarter of 2026
Gelonghui, May 9, 丨 Sanbo Neurology (301293.SZ) said during a survey of specific subjects that the company is constructing a new Beijing Dongba Campus project and is expected to complete construction by the end of 2025 and open in the first quarter of 2026. After the construction of the new hospital area is completed, the scope of medical facilities and medical service business will be expanded. The number of open beds is expected to increase from 254 to 480, and high-end beds will be set up; the number of operating rooms will increase from 6 to 14. At the same time, according to actual business development needs, Beijing Sanbo will add radiotherapy and rehabilitation services in the future. With geographical location, regional space, hardware facilities, and medical service standards
Sanbo Neurology (301293.SZ): 84.1915 million restricted shares will be listed and circulated on May 10, accounting for 53.13% of the total share capital
Zhitong Finance App News, Sanbo Neuroscience (301293.SZ) issued an announcement. The restricted shares listed and circulated by the company are limited-sale shares before the company's initial public offering. The number of shareholders whose sales restrictions have been lifted is 34, and the number of shares is 84.1915 million shares, accounting for 53.13% of the company's total share capital. The sales restriction period is 12 months from the date of the company's initial public offering of shares and listing. The listing and circulation date for the shares whose sales restrictions have been lifted is May 10, 2024 (Friday).
Sanbo Brain Science (301293.SZ) announced first-quarter results, net profit of 334.44,600 yuan, an increase of 35.29%
Sanbo Neurology (301293.SZ) released its report for the first quarter of 2024. The company's revenue was 3.37...
Sanbo Neurology (301293.SZ): 2023 net profit of 78.2381 million yuan, plans to convert 10 to 3 of 0.95 yuan
Gelonghui, April 18 | Sanbo Brain Science (301293.SZ) announced the 2023 annual report. In 2023, the company achieved operating income of 1,313 billion yuan, an increase of 22.73%; net profit attributable to shareholders of listed companies was 78.2381 million yuan, an increase of 23.31% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 93.593 million yuan, an increase of 79.74% year on year; basic income per share is 0.54 yuan; it is proposed to distribute a cash dividend of 0.95 yuan (tax included) for every 10 shares to all shareholders, with capital reserves All shareholders increase for every 10 shares
No Data